Financhill
Buy
73

LQDA Quote, Financials, Valuation and Earnings

Last price:
$35.81
Seasonality move :
2.66%
Day range:
$29.41 - $38.16
52-week range:
$11.26 - $38.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.27x
P/B ratio:
141.47x
Volume:
8M
Avg. volume:
1.5M
1-year change:
187.8%
Market cap:
$3.1B
Revenue:
$14M
EPS (TTM):
-$1.43

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LQDA
Liquidia Corp.
$84.9M $0.27 2667.32% -50.89% $44.00
AIM
AIM ImmunoTech
-- -$0.09 -23.08% -53.85% $4.50
ARMP
Armata Pharmaceuticals, Inc.
$1.5M -$0.42 19.84% -177.23% $9.00
BRKR
Bruker Corp.
$958.3M $0.65 -2.17% 619.12% $53.14
ITGR
Integer Holdings Corp.
$462.7M $1.70 2.37% 88.24% $85.57
MRK
Merck & Co., Inc.
$16.2B $2.04 5.87% -31.4% $111.62
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LQDA
Liquidia Corp.
$35.86 $44.00 $3.1B -- $0.00 0% 44.27x
AIM
AIM ImmunoTech
$0.04 $4.50 $2.8M -- $0.00 0% 13.27x
ARMP
Armata Pharmaceuticals, Inc.
$7.05 $9.00 $256.1M -- $0.00 0% 58.48x
BRKR
Bruker Corp.
$54.46 $53.14 $8.3B 77.08x $0.05 0.37% 2.40x
ITGR
Integer Holdings Corp.
$84.31 $85.57 $3B 35.30x $0.00 0% 1.63x
MRK
Merck & Co., Inc.
$110.53 $111.62 $274.3B 14.62x $0.85 2.97% 4.36x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LQDA
Liquidia Corp.
90.03% 0.097 10.09% 1.88x
AIM
AIM ImmunoTech
48.41% 0.745 17.25% 0.71x
ARMP
Armata Pharmaceuticals, Inc.
216.44% 3.342 164.57% 0.11x
BRKR
Bruker Corp.
45.23% 1.043 40.19% 0.76x
ITGR
Integer Holdings Corp.
42.89% -0.308 36.21% 2.27x
MRK
Merck & Co., Inc.
44.38% -0.108 20.79% 1.06x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LQDA
Liquidia Corp.
$50.9M $1.8M -79.94% -221.75% 3.25% -$10.7M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
ARMP
Armata Pharmaceuticals, Inc.
$789K -$7.8M -57.86% -- -670.92% -$4.5M
BRKR
Bruker Corp.
$399.6M $55.2M -0.56% -1.2% 6.42% -$54.1M
ITGR
Integer Holdings Corp.
$108.3M $53.6M 2.99% 5.26% 11.49% $46.3M
MRK
Merck & Co., Inc.
$13B $7.5B 22.23% 39.63% 43.43% $6.8B

Liquidia Corp. vs. Competitors

  • Which has Higher Returns LQDA or AIM?

    AIM ImmunoTech has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -10571.43%. Liquidia Corp.'s return on equity of -221.75% beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    LQDA
    Liquidia Corp.
    93.65% -$0.04 $221.2M
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About LQDA or AIM?

    Liquidia Corp. has a consensus price target of $44.00, signalling upside risk potential of 22.7%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Liquidia Corp., analysts believe AIM ImmunoTech is more attractive than Liquidia Corp..

    Company Buy Ratings Hold Ratings Sell Ratings
    LQDA
    Liquidia Corp.
    7 0 1
    AIM
    AIM ImmunoTech
    1 0 0
  • Is LQDA or AIM More Risky?

    Liquidia Corp. has a beta of 0.484, which suggesting that the stock is 51.629% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

  • Which is a Better Dividend Stock LQDA or AIM?

    Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LQDA or AIM?

    Liquidia Corp. quarterly revenues are $54.3M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Liquidia Corp.'s net income of -$3.5M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.27x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LQDA
    Liquidia Corp.
    44.27x -- $54.3M -$3.5M
    AIM
    AIM ImmunoTech
    13.27x -- $35K -$3.7M
  • Which has Higher Returns LQDA or ARMP?

    Armata Pharmaceuticals, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -2301.55%. Liquidia Corp.'s return on equity of -221.75% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    LQDA
    Liquidia Corp.
    93.65% -$0.04 $221.2M
    ARMP
    Armata Pharmaceuticals, Inc.
    68.08% -$0.74 $82.1M
  • What do Analysts Say About LQDA or ARMP?

    Liquidia Corp. has a consensus price target of $44.00, signalling upside risk potential of 22.7%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 27.66%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

    Company Buy Ratings Hold Ratings Sell Ratings
    LQDA
    Liquidia Corp.
    7 0 1
    ARMP
    Armata Pharmaceuticals, Inc.
    1 0 0
  • Is LQDA or ARMP More Risky?

    Liquidia Corp. has a beta of 0.484, which suggesting that the stock is 51.629% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.

  • Which is a Better Dividend Stock LQDA or ARMP?

    Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LQDA or ARMP?

    Liquidia Corp. quarterly revenues are $54.3M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Liquidia Corp.'s net income of -$3.5M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.27x versus 58.48x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LQDA
    Liquidia Corp.
    44.27x -- $54.3M -$3.5M
    ARMP
    Armata Pharmaceuticals, Inc.
    58.48x -- $1.2M -$26.7M
  • Which has Higher Returns LQDA or BRKR?

    Bruker Corp. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -6.8%. Liquidia Corp.'s return on equity of -221.75% beat Bruker Corp.'s return on equity of -1.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    LQDA
    Liquidia Corp.
    93.65% -$0.04 $221.2M
    BRKR
    Bruker Corp.
    46.44% -$0.41 $4.5B
  • What do Analysts Say About LQDA or BRKR?

    Liquidia Corp. has a consensus price target of $44.00, signalling upside risk potential of 22.7%. On the other hand Bruker Corp. has an analysts' consensus of $53.14 which suggests that it could fall by -2.42%. Given that Liquidia Corp. has higher upside potential than Bruker Corp., analysts believe Liquidia Corp. is more attractive than Bruker Corp..

    Company Buy Ratings Hold Ratings Sell Ratings
    LQDA
    Liquidia Corp.
    7 0 1
    BRKR
    Bruker Corp.
    7 5 1
  • Is LQDA or BRKR More Risky?

    Liquidia Corp. has a beta of 0.484, which suggesting that the stock is 51.629% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.854%.

  • Which is a Better Dividend Stock LQDA or BRKR?

    Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.37% to investors and pays a quarterly dividend of $0.05 per share. Liquidia Corp. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LQDA or BRKR?

    Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Liquidia Corp.'s net income of -$3.5M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.27x versus 2.40x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LQDA
    Liquidia Corp.
    44.27x -- $54.3M -$3.5M
    BRKR
    Bruker Corp.
    2.40x 77.08x $860.5M -$58.5M
  • Which has Higher Returns LQDA or ITGR?

    Integer Holdings Corp. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 8.5%. Liquidia Corp.'s return on equity of -221.75% beat Integer Holdings Corp.'s return on equity of 5.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    LQDA
    Liquidia Corp.
    93.65% -$0.04 $221.2M
    ITGR
    Integer Holdings Corp.
    23.21% $1.11 $3.1B
  • What do Analysts Say About LQDA or ITGR?

    Liquidia Corp. has a consensus price target of $44.00, signalling upside risk potential of 22.7%. On the other hand Integer Holdings Corp. has an analysts' consensus of $85.57 which suggests that it could grow by 1.5%. Given that Liquidia Corp. has higher upside potential than Integer Holdings Corp., analysts believe Liquidia Corp. is more attractive than Integer Holdings Corp..

    Company Buy Ratings Hold Ratings Sell Ratings
    LQDA
    Liquidia Corp.
    7 0 1
    ITGR
    Integer Holdings Corp.
    2 6 0
  • Is LQDA or ITGR More Risky?

    Liquidia Corp. has a beta of 0.484, which suggesting that the stock is 51.629% less volatile than S&P 500. In comparison Integer Holdings Corp. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.493%.

  • Which is a Better Dividend Stock LQDA or ITGR?

    Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Integer Holdings Corp. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LQDA or ITGR?

    Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Integer Holdings Corp. quarterly revenues of $466.6M. Liquidia Corp.'s net income of -$3.5M is lower than Integer Holdings Corp.'s net income of $39.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Integer Holdings Corp.'s PE ratio is 35.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.27x versus 1.63x for Integer Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LQDA
    Liquidia Corp.
    44.27x -- $54.3M -$3.5M
    ITGR
    Integer Holdings Corp.
    1.63x 35.30x $466.6M $39.7M
  • Which has Higher Returns LQDA or MRK?

    Merck & Co., Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 33.68%. Liquidia Corp.'s return on equity of -221.75% beat Merck & Co., Inc.'s return on equity of 39.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    LQDA
    Liquidia Corp.
    93.65% -$0.04 $221.2M
    MRK
    Merck & Co., Inc.
    75.59% $2.32 $93.3B
  • What do Analysts Say About LQDA or MRK?

    Liquidia Corp. has a consensus price target of $44.00, signalling upside risk potential of 22.7%. On the other hand Merck & Co., Inc. has an analysts' consensus of $111.62 which suggests that it could grow by 0.98%. Given that Liquidia Corp. has higher upside potential than Merck & Co., Inc., analysts believe Liquidia Corp. is more attractive than Merck & Co., Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    LQDA
    Liquidia Corp.
    7 0 1
    MRK
    Merck & Co., Inc.
    15 12 0
  • Is LQDA or MRK More Risky?

    Liquidia Corp. has a beta of 0.484, which suggesting that the stock is 51.629% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

  • Which is a Better Dividend Stock LQDA or MRK?

    Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.97% to investors and pays a quarterly dividend of $0.85 per share. Liquidia Corp. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LQDA or MRK?

    Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Liquidia Corp.'s net income of -$3.5M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 44.27x versus 4.36x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LQDA
    Liquidia Corp.
    44.27x -- $54.3M -$3.5M
    MRK
    Merck & Co., Inc.
    4.36x 14.62x $17.2B $5.8B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Shopify Stock a Good Buy Now?
Is Shopify Stock a Good Buy Now?

eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…

Will The Magnificent 7 Stocks Go Up This Year?
Will The Magnificent 7 Stocks Go Up This Year?

2025 was another banner year for the Magnificent Seven stocks,…

Why Did Planet Labs Stock Rally So Much?
Why Did Planet Labs Stock Rally So Much?

Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
65
Is GOOG Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Buy
51
Is GOOGL Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Alerts

Buy
100
ATGL alert for Jan 10

Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.

Buy
71
NAIL alert for Jan 10

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.

Buy
54
LGIH alert for Jan 10

LGI Homes, Inc. [LGIH] is up 13.81% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock